We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Icomes Lab Demonstrates World's Smallest and Lightest Electronic Pipette for PCR Testing at MEDICA 2021

By LabMedica International staff writers
Posted on 18 Nov 2021
Image: Pipetty Electronic Pipette (Photo courtesy of ICOMES LAB Co., Ltd.)
Image: Pipetty Electronic Pipette (Photo courtesy of ICOMES LAB Co., Ltd.)

ICOMES LAB Co., Ltd. (Iwate, Japan) demonstrated the world's smallest and lightest electronic pipette with a length of 135mm and a weight of 75g at MEDICA 2021.

ICOMES pipetty is the world's smallest, lightest, pen-type electronic pipette. This high-precision lightweight electronic pipette is ideal for continuous dispensing of PCR testing. It continuously dispenses a fixed number of times automatically and compensates a dispensing volume for preventing accuracy deterioration due to hand warming.

ICOMES also demonstrated its pipetty Smart electric pipette that can be controlled by a smartphone app. pipetty Smart is the world's first pipette with wireless communication function.Equipped with Bluetooth technology, it reduces the burden of routine work on the operator by setting the dispensing protocol. It automatically creates a log file after dispensing operation, leaving evidence for post-checks. pipetty Smart is equipped with a smartphone numeric keypad and voice input function to improve work efficiency.

Related Links:
ICOMES LAB Co., Ltd. 

New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Multi-Chamber Washer-Disinfector
WD 390
New
Rapid Sepsis Test
SeptiCyte RAPID

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG